Please ensure Javascript is enabled for purposes of website accessibility

AbbVie to Test HIV Drug as a Potential Coronavirus Treatment

By Prosper Junior Bakiny - Mar 10, 2020 at 10:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The antiviral combination treatment Kaletra has reportedly shown promise against COVID-19 in China.

As the COVID-19 epidemic continues to spread worldwide, the race to find treatments and vaccines for the disease is heating up. Among those searching for solutions is AbbVie (ABBV -0.38%), which is investigating whether its HIV drug Kaletra could be a treatment for COVID-19.

Kaletra is a combination of lopinavir and ritonavir, both of which are antiviral drugs that prevent HIV from multiplying inside a patient's body. There have been reports coming from China that Kaletra (also sold as Aluvia) has shown effectiveness as a treatment for COVID-19, but AbbVie has no access to the clinical data involved, and therefore could not assess the accuracy of those reports. 

However, the company recently announced that it was partnering with health agencies worldwide to study the efficacy of Kaletra as a treatment for COVID-19, among them the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), and European health authorities. 

Microscopic views of the Coronavirus

Image Source: Getty Images.

The number of confirmed cases of COVID-19 in the U.S. now exceeds 750, the worldwide total has topped 109,000, and the CDC recently warned that this disease outbreak could continue until 2021. If one of the biotech companies working to find a treatment or a vaccine for the disease were to succeed, it could profit handsomely. With that in mind, investors in the healthcare sector should continue to monitor AbbVie, Gilead Sciences (GILD 0.51%), Inovio Pharmaceuticals (INO 13.71%), and Novavax (NVAX 17.46%), all of which are racing to find an effective response to the novel coronavirus.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$150.00 (-0.38%) $0.57
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.80 (0.51%) $0.33
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$55.29 (17.46%) $8.22
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.99 (13.71%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.